Bristol-Myers Financial Statements From 2010 to 2022

BMYMP
 Stock
  

USD 1,287  0.00  0.00%   

Bristol-Myers Squibb financial statements provide useful quarterly and yearly information to potential Bristol-Myers Squibb investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bristol-Myers Squibb financial statements helps investors assess Bristol-Myers Squibb's valuation, profitability, and current liquidity needs.
Bristol-Myers Squibb does not presently have any fundamental signals for analysis.
.
  
Check Bristol-Myers Squibb financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol-Myers main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Bristol-Myers financial statements analysis is a perfect complement when working with Bristol-Myers Squibb Valuation or Volatility modules. It can also supplement various Bristol-Myers Squibb Technical models . Continue to the analysis of Bristol-Myers Squibb Correlation against competitors.

Bristol-Myers Book Value Per Share Analysis

Bristol-Myers Squibb's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Book Value per Share 
 = 
Common Equity 
Average Shares 
More About Book Value Per Share | All Equity Analysis

Current Bristol-Myers Squibb Book Value Per Share

    
  7.55 X  
Most of Bristol-Myers Squibb's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol-Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Compare to competition

In accordance with the recently published financial statements, the book value per share of Bristol-Myers Squibb is about 7.55 times. This is 544.12% lower than that of the Healthcare sector and 41.34% lower than that of the Drug Manufacturers - Major industry. The book value per share for all United States stocks is 99.61% higher than that of the company.

Bristol-Myers Squibb Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bristol-Myers Squibb's current stock value. Our valuation model uses many indicators to compare Bristol-Myers Squibb value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol-Myers Squibb competition to find correlations between indicators driving Bristol-Myers Squibb's intrinsic value. More Info.
Bristol-Myers Squibb is number one stock in cash flow from operations category among related companies. It is number one stock in total asset category among related companies fabricating about  6.74  of Total Asset per Cash Flow from Operations. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol-Myers Squibb by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol-Myers Squibb's OTC Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol-Myers Squibb's earnings, one of the primary drivers of an investment's value.

About Bristol-Myers Squibb Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol-Myers Squibb income statement, its balance sheet, and the statement of cash flows. Bristol-Myers Squibb investors use historical funamental indicators, such as Bristol-Myers Squibb's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bristol-Myers Squibb investors may use each financial statement separately, they are all related. The changes in Bristol-Myers Squibb's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol-Myers Squibb's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol-Myers Squibb Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol-Myers Squibb. Please read more on our technical analysis and fundamental analysis pages.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol-Myers Squibb without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Correlations Now

   

Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Pair Trading with Bristol-Myers Squibb

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Bristol-Myers Squibb could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol-Myers Squibb when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol-Myers Squibb - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol-Myers Squibb to buy it.
The correlation of Bristol-Myers Squibb is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol-Myers Squibb moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol-Myers Squibb can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Bristol-Myers Squibb Correlation against competitors. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for analysis

When running Bristol-Myers Squibb price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Please note, there is a significant difference between Bristol-Myers Squibb's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol-Myers Squibb value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.